This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Bayer/Evotec Endometriosis Program

Bayer AG

Description: Evotec and Bayer are developing clinical candidates for the treatment of endometriosis.

Deal Structure: Bayer and Evotec
In October 2012, Evotec announced that Evotec and Bayer Pharma have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Both parties will contribute innovative drug targets and high quality technology infrastructures and will share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in the disease area of endometriosis. Bayer will be responsible for any subsequent clinical development and commercialisation. Evotec will receive EUR 12 million as an upfront payment. In total Evotec may receive pre-clinical, clinical and sales milestones of potentially up to approximately EUR 580 million, plus potential royalties of up to low double digit percent of net sales, depending on which party brought the compound to the collaboration and the successful development and approval of potential drug candidates.

Partners: Evotec AG

Bayer/Evotec Endometriosis Program News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug